Pandion’s immune-regulating platform attracts $80M B round
Pandion’s immune effectors can be mixed and matched with tissue-tethering antibodies, providing partnership opportunities across different diseases
Pandion raised $80 million in a series B round, triggered by a pancreas-focused partnership with Astellas and the clinical debut of its lead immune modulator. The modularity attracted Access Biotechnology to co-lead the round with Boxer Capital.
Additional new investors RA Capital and OrbiMed Advisors also participated in the round, as did existing investors Polaris Partners, Versant
